TARS Q1 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$78M+183.7% YoY

Gross Profit

$73M93.3% margin

Operating Income

-$26M-33.5% margin

Net Income

-$25M-32.1% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+18.0%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$501M

Total Liabilities

$158M

Stockholders' Equity

$342M

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$28M	+183.7%
Gross Profit	$73M	$26M	+181.7%
Operating Income	-$26M	-$38M	+30.3%
Net Income	-$25M	-$36M	+29.7%

Revenue Segments

Product

$78M100%